Implications of increasing pricing pressure regimes and required market strategies Advantages of trade to the generic and biosimilar industry Maximising growth opportunities to be gained from fast growing dynamic markets What is a sustainable price for a generic and how do you go about achieving it? Key Opinion Leader Perspectives and Impact on Adoption Rates for Biosimilars, Pricing Discounts & Rebates Trends in Costs and Pricing Moderator: Tommy Erdei, Global Joint Head of Pharmaceuticals and Life Sciences, Joint Head of European Healthcare Investment Banking,, Jefferies Group Rahul Garella, Senior Vice President, Par Pharmaceutical Companies, Inc.
World Generic Medicines Congress day 1
Registration
Generics and Biosimilars Commercial Strategy
Opening remarks from the chair
Generics market focus
Successful strategies to build new business, open up new markets and grow market share in MENA
Keynote Panel Discussion: The Future of the Affordable Medicine Industry - Mapping the Evolution and Development of the Biosimilar Sector
Speed networking
Morning refreshments
Biosimilars - A View From The Capital Markets
Lunch
PEER TO PEER ROUNDTABLES:
Advantages of trade to the generic and biosimilar industry?
Mr David Jauch, Global Regulatory Affairs and Government Relations Manager, Fresenius Kabi
Implications of increasing pricing pressure regimes and required market strategies
Maximising growth opportunities to be gained from fast growing dynamic markets
What is a sustainable price for a generic and how do you go about achieving it?
Generics
Afternoon Chair: Nitin Naik, Vice President-Global Life Sciences, Frost and Sullivan
Afternoon refreshments
Recent Challenges & opportunities with Generic R&D
How smaller generic companies are competing in challenging EU countries
Show me the money: making a profit with generics
Closing remarks from the chair
Drinks party